[PETDAG] QoQ Quarter Result on 31-Mar-2022 [#1]

Stock
[PETDAG] PETRONAS DAGANGAN BHD
Announcement Date
26-May-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
31-Mar-2022 [#1]
Profit Trend
QoQ- -13.63%
YoY- -38.0%
Quarter Report
Latest QR
Upcoming QR
PETDAG's Result
PETDAG's Financial Summary
View:
Show?
Quarter Result
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Revenue 9,498,779 10,130,694 9,501,101 7,618,323 7,057,356 5,200,662 5,143,990 50.34%
PBT 241,686 399,141 315,494 178,714 199,807 165,540 89,965 92.90%
Tax -93,044 -119,709 -76,080 -58,364 -61,722 -45,922 -7,600 428.77%
NP 148,642 279,432 239,414 120,350 138,085 119,618 82,365 48.06%
-
NP to SH 144,457 275,965 237,679 118,494 137,191 119,310 82,141 45.54%
-
Tax Rate 38.50% 29.99% 24.11% 32.66% 30.89% 27.74% 8.45% -
Total Cost 9,350,137 9,851,262 9,261,687 7,497,973 6,919,271 5,081,044 5,061,625 50.38%
-
Net Worth 5,742,164 5,801,771 5,632,884 5,444,127 5,583,211 5,632,884 5,613,015 1.52%
Dividend
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Div 397,381 198,690 109,279 49,672 258,298 198,690 99,345 151.34%
Div Payout % 275.09% 72.00% 45.98% 41.92% 188.28% 166.53% 120.94% -
Equity
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Net Worth 5,742,164 5,801,771 5,632,884 5,444,127 5,583,211 5,632,884 5,613,015 1.52%
NOSH 993,454 993,454 993,454 993,454 993,454 993,454 993,454 0.00%
Ratio Analysis
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
NP Margin 1.56% 2.76% 2.52% 1.58% 1.96% 2.30% 1.60% -
ROE 2.52% 4.76% 4.22% 2.18% 2.46% 2.12% 1.46% -
Per Share
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
RPS 956.14 1,019.74 956.37 766.85 710.39 523.49 517.79 50.34%
EPS 14.50 27.80 23.90 11.90 13.80 12.00 8.30 44.90%
DPS 40.00 20.00 11.00 5.00 26.00 20.00 10.00 151.34%
NAPS 5.78 5.84 5.67 5.48 5.62 5.67 5.65 1.52%
Adjusted Per Share Value based on latest NOSH - 993,454
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
RPS 956.14 1,019.74 956.37 766.85 710.39 523.49 517.79 50.34%
EPS 14.50 27.80 23.90 11.90 13.80 12.00 8.30 44.90%
DPS 40.00 20.00 11.00 5.00 26.00 20.00 10.00 151.34%
NAPS 5.78 5.84 5.67 5.48 5.62 5.67 5.65 1.52%
Price Multiplier on Financial Quarter End Date
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Date 30/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 -
Price 23.00 20.02 21.12 20.42 20.60 19.12 18.60 -
P/RPS 2.41 1.96 2.21 2.66 2.90 3.65 3.59 -23.27%
P/EPS 158.17 72.07 88.28 171.20 149.17 159.21 224.96 -20.87%
EY 0.63 1.39 1.13 0.58 0.67 0.63 0.44 26.95%
DY 1.74 1.00 0.52 0.24 1.26 1.05 0.54 117.69%
P/NAPS 3.98 3.43 3.72 3.73 3.67 3.37 3.29 13.49%
Price Multiplier on Announcement Date
31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 CAGR
Date 22/02/23 25/11/22 24/08/22 26/05/22 22/02/22 26/11/21 23/08/21 -
Price 22.12 22.08 21.94 21.12 19.98 19.90 18.80 -
P/RPS 2.31 2.17 2.29 2.75 2.81 3.80 3.63 -25.95%
P/EPS 152.12 79.49 91.71 177.07 144.68 165.70 227.38 -23.45%
EY 0.66 1.26 1.09 0.56 0.69 0.60 0.44 30.94%
DY 1.81 0.91 0.50 0.24 1.30 1.01 0.53 126.27%
P/NAPS 3.83 3.78 3.87 3.85 3.56 3.51 3.33 9.74%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment